Mike Maloney
Director, Immunology Clasp
Mike joined Clasp Therapeutics in March 2023 and led the nonclinical efforts supporting the advancement of the company’s first therapeutic candidate, CLSP-1025, into clinical trials. His work focuses on translating pHLA-targeted immunotherapies from discovery through IND-enabling development. Prior to Clasp, he worked at SQZ Biotechnologies on cell-based cancer vaccines for HPV-positive solid tumors, and earlier at Abpro, where he focused on the engineering of bispecific antibodies. He earned a BS in Molecular Biology from the University of Wisconsin–Madison and a PhD in Biology from MIT.
Seminars
Thursday 25th June 2026
Advancing T‑Cell Engagers Targeting Driver Mutations for Solid Tumors
11:30 am
- Discovery and engineering approaches for generating highly selective pHLA-targeted binders.
- Preclinical evaluation strategies, including functional activity, specificity, and safety assessment.
- Key learnings from advancing pHLA-targeted therapies from nonclinical development into the clinic, and implications for next-generation programs
